961-P: Comparison of Glucose Metrics by Capillary Blood Glucose and Continuous Glucose Monitoring among People with Type 2 Diabetes on Hemodialysis

Abstract

Background: Reliability of HbA1c in subjects with end-stage kidney disease treated with hemodialysis is poor. Capillary blood glucose (CBG) is widely used, but is limited to 2-4 values/day. Clinical guidelines recommend using continuous glucose monitoring (CGM) to assess glycemic control in this population, but there is limited data. Methods: Prospective observational study of insulin treated adults with type-2 diabetes (T2D) receiving hemodialysis. Subjects were instructed to wear a Dexcom G6-Pro and perform Nova StatStrip CBG at least 2-4/d for 10-days. We compared mean glucose, hypoglycaemia, and hyperglycaemia rates, time-in-target range (TIR), time above range (TAR), and time below range (TBR) between testing methods. Results: Glucose metrics are shown in Table 1. Conclusion: Compared to CBG, CGM provides a comprehensive glycemic evaluation in insulin-treated subjects with T2D on hemodialysis. CGM was superior in assessing glycemic control (TIR), detection of severe hyperglycemia and hypoglycemic excursions, particularly nocturnal and prolonged events. Safer treatment options assessed by CGM metrics are needed for this high-risk population. Disclosure R.J.Galindo: Consultant; Novo Nordisk, Eli Lilly and Company, Sanofi, Pfizer Inc., Bayer Inc., WW (Weight Watchers), Research Support; Novo Nordisk, Eli Lilly and Company, Dexcom, Inc. A.Y.G.Gerges: None. B.Moazzami: None. L.Peng: None. K.R.Tuttle: Consultant; Lilly, AstraZeneca, Gilead Sciences, Inc., Research Support; Bayer Inc., Boehringer Ingelheim (Canada) Ltd., Novo Nordisk, Goldfinch Bio, Inc., Traveere Pharmaceuticals. G.Umpierrez: Research Support; Abbott, Dexcom, Inc., Baxter.